Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Limited Health Literacy During Middle Adulthood and Its Associations with Health Self-Management and Physical Function.

Journal of general internal medicine·2026
Same author

The Role of Microbiome-Associated Metabolites and Their Clinical Implications in Traumatic Brain Injury: A Scoping Review.

Neurocritical care·2026
Same author

Initiation of first-generation antihistamines during pregnancy and gestational restless legs syndrome: a secondary analysis of the nuMoM2b cohort.

American journal of obstetrics & gynecology MFM·2026
Same author

When Function Counts: Aligning Pediatric Critical Care with Outcomes that Matter.

Neurocritical care·2026
Same author

Multidimensional Sleep Health and Cognitive Risk in Midlife Primary Care: Comparing Questionnaires.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical validation of MyCog Mobile: development of a parsimonious and clinically interpretable prediction model for mild cognitive impairment.

JAMIA open·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

Technology and Dementia Preconference.

Stephanie Ruth Young1, Julia Yoshino-Benavente1, Richard C Gershon1

  • 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 23, 2025
PubMed
Summary
This summary is machine-generated.

The upgraded MyCog cognitive screening tool demonstrates high reliability and validity for older adults in primary care. Usability enhancements did not compromise its psychometric properties, supporting its continued clinical use for early cognitive impairment detection.

More Related Videos

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Area of Science:

  • Gerontology
  • Cognitive Science
  • Health Informatics

Background:

  • Early detection of cognitive impairment (CI) in adults over 65 is crucial, yet primary care settings identify less than half of affected patients.
  • The MyCog app, a NIH-funded, tablet-based cognitive screener, integrates with electronic health records to aid early CI detection and decision-making support.
  • Feedback from clinical sites (Northwestern Medicine, Oak Street Health, Access Community Health Network) has led to significant improvements in the MyCog app's user experience and interface.

Purpose of the Study:

  • To present evidence from the construct validation of the upgraded MyCog app.
  • To discuss the usability implications of the upgraded MyCog app in clinical settings.
  • To evaluate the psychometric properties of the enhanced MyCog cognitive screener.

Main Methods:

  • A community sample (n=200, mean age=73) using the upgraded MyCog was compared to an age-matched sample using the original MyCog.
  • Confirmatory factor analysis was used to evaluate internal consistency and construct validity.
  • Bayesian differential item functioning analysis assessed the equivalence between the original MyCog and MyCog 2.0.

Main Results:

  • High internal consistency was found for executive function (rsb=.92) and episodic memory tests (ωt=.84).
  • A two-factor model demonstrated excellent fit, indicating that the tests measure related but distinct constructs, outperforming a one-factor model.
  • No differential item functioning was observed for episodic memory or executive functioning accuracy between the two versions; however, response times on five executive function items differed.

Conclusions:

  • The findings support the upgraded MyCog as a reliable and valid self-administered cognitive screener suitable for older adults.
  • Usability improvements in the MyCog app did not compromise its psychometric validity, confirming its suitability for continued clinical use.
  • Further clinical validation studies for the MyCog app are planned.